United Capital Financial Advisors LLC Makes New $857,000 Investment in Illumina, Inc. $ILMN

United Capital Financial Advisors LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,875 shares of the life sciences company’s stock, valued at approximately $857,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital World Investors raised its position in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. BlackRock Inc. bought a new position in Illumina in the 2nd quarter worth about $3,374,423,000. State Street Corp grew its position in Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC grew its position in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ILMN. Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Finally, Guggenheim upped their price objective on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Stock Performance

Illumina stock opened at $215.59 on Monday. The business has a 50-day simple moving average of $194.05 and a two-hundred day simple moving average of $155.87. The company has a market cap of $32.55 billion, a P/E ratio of 40.22, a P/E/G ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 138,379 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the completion of the sale, the director directly owned 1,033,910 shares of the company’s stock, valued at approximately $236,651,659.90. This represents a 11.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,799,688 shares of company stock valued at $379,517,231. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.